JP5749426B2 - Erythrocyte deformability improver - Google Patents

Description

  The present invention relates to a red blood cell deformability improving agent.

  Red blood cells are a kind of cell component contained in blood, and hemoglobin contained in cells binds to oxygen and has a function of transporting oxygen to tissues in the body.

  The red blood cells have a deformability even though they have a diameter of about 8 μm and are larger than the average diameter of the capillaries, and can pass through the capillaries.

  However, when the deformability of erythrocytes is reduced, the dent disk-shaped erythrocytes swell in a ball shape, and not only can not pass through capillaries, but also become clogged with blood vessels narrowed by arteriosclerosis, It was the cause of diseases such as cerebral infarction and myocardial infarction.

  Therefore, many kinds of red blood cell deformability improving agents have been developed as drugs for improving the deformability of red blood cells (see, for example, Patent Documents 1 to 3).

Japanese Patent Laid-Open No. 7-61933 JP-A-8-67635 JP 2002-128679 A

  The present invention provides a erythrocyte deformability improving agent having a high immediate effect that can improve the deformability of red blood cells by acting on the cells of red blood cells to activate the cells of red blood cells themselves.

  Therefore, in the present invention according to claim 1, the erythrocyte deformability improving agent contains glutathione, selenium and vitamin B1.

  Further, in the present invention according to claim 2, in the present invention according to claim 1, 50 to 400 mg of glutathione, 1 to 100 μg of selenium, and 1 to 50 mg of vitamin B1 are contained.

In the present invention according to claim 3, in the present invention according to claim 1 or 2, the glutathione is contained as a glutathione-containing yeast , and the selenium is contained as a selenium-containing yeast . .

  In the erythrocyte deformability improving agent according to the present invention, glutathione, selenium and vitamin B1 can act on erythrocyte cells to activate erythrocyte cells, thereby improving erythrocyte deformability, Moreover, it was confirmed that the immediate effect was high.

The graph which shows a red blood cell slit passage test result. Same photo. The graph which shows a red blood cell slit passage test result. Same photo.

  Hereinafter, specific contents of the red blood cell deformability improving agent according to the present invention will be described.

  The erythrocyte deformability improving agent according to the present invention is a drug consisting of glutathione, selenium and vitamin B1, and glutathione, selenium and vitamin B1 directly act on erythrocyte cells to activate erythrocyte cells, and the erythrocyte deformability In addition, it has a high immediate effect.

  In order to prove this, the cases of Example 1 (Case 1) and Example 2 (Case 2) are shown below.

  First, a case in which a drug consisting of glutathione, selenium, and vitamin B1 is continuously taken is shown.

In this case, the drug with the following composition was taken for 24 days after breakfast from Monday to Friday, and on Saturdays and Sundays it was closed.
Pharmaceutical composition Glutathione: 100mg
Selenium: 50μg
Vitamin B1: 25mg

  Then, an erythrocyte slit passage test (MCFUN method: Micro Channel Array Flow Analyzer) was performed at 10 o'clock after oral administration on the 12th day after the start of internal use and after the start of internal use, and measurement of the slit passage time of 100 μL of blood was performed. The results are shown in Table 1, FIG. 1 and FIG.

  As shown in Table 1 and FIG. 1 (×), in case 1, before the start of oral administration, only 80 μL of blood can pass through the slit in 58.5 seconds, and then the time is over, resulting in 100 μL of blood. The transit time could not be measured.

  In addition, as shown in FIG. 2 (a), before the start of oral administration, when 70 μL of blood passes, the blood is clogging in most of the 18 slits, and the deformability of erythrocytes is reduced. It was confirmed that the dent disc-shaped erythrocytes were swollen into a ball.

  On the other hand, as shown in Table 1 and Figure 1 (marked with ●), 100 μL of blood passed in 59.5 seconds after the start of oral administration, and it was confirmed that blood passed clearly in a shorter time than before the start of oral administration. It was done.

  In addition, as shown in FIG. 2 (b), after starting oral administration, when 70 μL of blood has passed, blood is clogged in 7 of 18 slits, but blood is good in 11 slits. It was confirmed that the deformability of erythrocytes was improved and the erythrocytes were restored from the ball shape to the original dent disk shape.

  From this case, by continuously taking a drug consisting of glutathione, selenium and vitamin B1, glutathione, selenium and vitamin B1 act directly on erythrocyte cells to activate erythrocyte cells, and to improve the erythrocyte deformability. It was confirmed that it can be improved.

  Next, a case immediately after taking a drug composed of glutathione, selenium and vitamin B1 is shown.

In this case 2, a medicine having the following composition was taken as No. 2 HPMC hard capsules.
Pharmaceutical composition Glutathione: 100.8mg
Selenium: 10μg
Vitamin B1: 205mg
However, glutathione 100.8 mg was taken as 112 mg 6 grains of yeast containing 15% glutathione, and selenium 10 μg was taken as 0.84 mg 6 grains of yeast containing 0.2% selenium.

  Then, an erythrocyte slit passage test (MCFUN method: Micro Channel Array Flow Analyzer) was performed before and 20 minutes after taking, and the slit passage time of 100 μL of blood was measured. The results are shown in Table 2, FIG. 3 and FIG.

  As shown in Table 2 and FIG. 3 (x mark), in the case of Case 2, it was confirmed that 100 μL of blood passed in 77.9 seconds before taking.

  In addition, as shown in FIG. 4 (a), when 75 μL of blood passed before taking, blood was clogged at 11 locations in 18 slits, and the deformability of red blood cells was reduced. It was confirmed that the medium-recessed disk-shaped red blood cells were swollen into a ball shape.

  On the other hand, as shown in Table 2 and FIG. 3 (● marks), 100 μL of blood passed in 51.0 seconds after taking, and it was confirmed that blood passed clearly in a shorter time than before taking. .

  In addition, as shown in FIG. 4 (b), after 75 μL of blood has passed, the blood is clogged at only two of the 18 slits after taking, but the blood is good at the 16 slits. It was confirmed that the deformability of erythrocytes was improved and the erythrocytes were restored from the ball shape to the original dent disk shape.

  From this case, by taking a drug consisting of glutathione, selenium and vitamin B1, glutathione, selenium and vitamin B1 act directly on erythrocyte cells to activate erythrocyte cells and improve erythrocyte deformability It was confirmed that Moreover, it was confirmed that the immediate effect of the drug is high by using glutathione or selenium as glutathione-containing yeast or selenium-containing yeast, or encapsulating it in a capsule.

  From the above Examples 1 and 2, the drug consisting of glutathione, selenium and vitamin B1 can act on the cells of erythrocytes by glutathione, selenium and vitamin B1, thereby activating the cells of erythrocytes. It was confirmed that the deformability of erythrocytes can be improved and that the immediate effect is high.

  In addition, the said Example 1 and Example 2 only illustrated the typical example of the case of the erythrocyte deformability improving agent which concerns on this invention, 50-400 mg of glutathione, 1-100 micrograms of selenium, vitamin B1. The same effects as in the above case were confirmed even when drugs of various compositions containing 1 to 50 mg were taken or intravenously administered.

  Below, the effect of the red blood cell deformability improving agent according to the present invention will be considered.

  In the evolution process, the cells evolved to cells called Callioblastea in the era when the atmosphere on the earth contained almost no oxygen, forming primitive cell bodies, and then cyanobacteria consisting of cyanobacteria on the earth. When oxygen is generated and a large amount of oxygen is contained in the atmosphere, mitochondria that utilize oxygen are born, and these mitochondria are parasitic on the primitive cell body and have evolved into the current symbiotic cells.

  The mitochondria in the cell act as vitamin B1 as an essential nutrient, while the primitive cell body in the cell contains glucose (hexose) to pentose phosphate with glutathione, selenium, and vitamin B1 as nutrients. It is thought to be active by moving the pentose phosphate pathway that makes (PRPP). In addition, living organisms make DNA and RNA using pentose phosphate, transcribe DNA gene information into mRNA in the cell, and bind amino acids on rRNA from the information to make various kinds necessary for biochemical reaction. Is producing protein.

  In particular, erythrocytes are considered to be deformed by the primordial cell bodies in the cells because the nuclei disappear after generation and have a hollow shape.

  Therefore, by taking a drug consisting of glutathione, selenium and vitamin B1, glutathione, selenium and vitamin B1 can directly act on erythrocyte cells to activate erythrocyte cells. It is considered that the deformability can be improved.

  Since the erythrocyte deformability improving agent according to the present invention contains vitamin B1, this vitamin B1 can act on the mitochondria to activate the mitochondria, and the action of vitamin B1 in the liver Glutathione production can be promoted, which can also improve red blood cell deformability.

Claims (3)

  An erythrocyte deformability improving agent comprising glutathione, selenium and vitamin B1.   The red blood cell deformability improving agent according to claim 1, comprising 50 to 400 mg of glutathione, 1 to 100 µg of selenium, and 1 to 50 mg of vitamin B1. The erythrocyte deformability improving agent according to claim 1 or 2, wherein the glutathione is contained as a glutathione-containing yeast and the selenium is contained as a selenium-containing yeast .

Images